Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.45 EUR | -0.95% | -5.43% | +13.71% |
Apr. 23 | Futures up; wait for Eurozone PMI | AN |
Apr. 22 | Mib bearish; DiaSorin closes ahead of all | AN |
Strengths
- With a P/E ratio at 10.37 for the current year and 7.53 for next year, earnings multiples are highly attractive compared with competitors.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.68 for the 2024 fiscal year.
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart - Surperformance
Sector: Advertising & Marketing
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+13.71% | 62.53M | - | ||
+37.42% | 2.22B | B | ||
-1.00% | 64.87M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ALK Stock
- Ratings Alkemy S.p.A.